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Background: The purpose of the study was to examine lung cancer
patients’ knowledge, attitudes, and behavior regarding clinical trials
and to develop an effective intervention for increasing patient
knowledge and awareness of clinical trials for lung cancer patients.
Methods: Qualitative semistructured, in-depth interviews were con-
ducted with (1)new patients who had not yet interacted with their
physicians, (2) existing patients who had participated in a clinical
trial, and (3) existing patients who had not been offered a trial.
Findings from the interviews led to the creation of a letter that was
sent to all new patients before their first appointment, explaining that
offering a clinical trial at this hospital was the norm, to expect this
discussion, and the option of standard treatment was always available.
Results: Results showed new patients and established patients had
similar perceptions of trials—the fear of being a guinea pig, offering
a trial meant no hope, and misconception of purpose. Existing
patients who had participated in a trial expressed positive benefits of
trial participation, even if their health did not improve. A year after the
letter process was initiated, accrual rates increased 18% and approxi-
mately 81% of all eligible lung cancer patients were in a trial.
Conclusions: The letter, addressing patient’s preexisting fears about
being offered a clinical trial, appears to show some initial success in
improving clinical trial accrual.
Key Words: Clinical trials, Patient-physician communication, Be-
havioral research, Psychosocial intervention.
(J Thorac Oncol. 2007;2: 191–196)
Clinical research and trials offer great promise and oppor-tunities for cancer patients; yet in the area of thoracic
cancers, improvements in life expectancy and cure rates have
not seen substantial progress in the past 15 years.1 Deficien-
cies in lung cancer patients in clinical trials may be one
reason for this lack of progress. For example, even though
lung cancers comprise the highest percentage of U.S. cancer
deaths, there are fewer lung cancer trials than colorectal
cancer and leukemia trials; thus, compared with patients with
colorectal cancer and leukemia, lung cancer patients are
underrepresented in clinical trials (Table 1).2 Additionally,
underrepresentation of patients in clinical studies, especially
with elderly populations, may be associated with the selection
process. Patients who have a better prognosis and can better
tolerate treatment are more likely to be offered a trial.3 The
underrepresentation of lung cancer patients, particularly the
over-65 population, affects the ability to generalize the results
to the whole population with lung cancer.3
Lung cancer patients comprise a unique type of cancer
patient. There is often a stigma associated with their disease
due to public presupposition that the cancer was caused by
the risk behavior of smoking. Lung cancer patients tend to
require more assurances and attention to their psychological
needs, thus requiring more physician attention than patients
with other types of cancer.4 At the same time, guilt and shame
among former tobacco users and a sense of hopelessness
about their condition inhibits lung cancer patients from using
support services or seeking mental health services.5 Several
areas of research conclude that lung cancer patients perceive
less money and time are spent on lung cancer research due to
the notion that it is primarily a self-inflicted disease.6 Fur-
thermore, a review of the psychosocial issues associated with
lung cancer reveals clinical interventions are less likely to be
offered to lung cancer patients, and they tend to perceive that
they have fewer options than other cancer patients.7 Due to
these unique issues faced by lung cancer patients, there is a
pressing need to create materials specific to this type of cancer.
In this study, we examined lung cancer patients’ knowl-
edge, attitudes, and behaviors regarding clinical trials for lung
cancer. The goal of this research effort was to identify trends
among lung cancer patients’ perceptions that may lead to
effective interventions for increasing patient knowledge and
awareness of clinical trials. A successful intervention was
developed based on response to patient needs aimed to ensure
patients were making fully informed decisions about clinical
trials and not decisions based on inaccurate general percep-
tions.
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METHODS
Formative Research Phase
To examine lung cancer patients’ perceptions of clini-
cal trials and to identify the barriers and benefits associated
with participating in a clinical trial, qualitative, semistruc-
tured in-depth interviews were conducted with three catego-
ries of thoracic patients from an National Cancer Institute
Comprehensive Cancer Center: (1) new patients who had not
yet interacted with their physician (n  10), (2) existing
patients who had participated in a clinical trial (n  18), (3)
existing patients who had not been offered a trial (n  15).
Sample
Dimensional sampling was used to guide participant
selection.8,9 Dimensional sampling is an intentional selection
of respondents who meet the criteria of interest and represent
variety within those criteria. Patients were identified through
the hospital database as either new patients or existing pa-
tients. Researchers reviewed the Thoracic Program’s appoint-
ment schedules for Mondays and Wednesdays during an
8-week period to identify patients who met the following
inclusion criteria: (1) 18 years of age or older, (2) English
speaking, (3) new patients (no previous encounter with a
physician in the thoracic clinic or hospital), (4) existing
patients (at least two previous encounters with a physician in
the thoracic clinic).
This study was approved through the University of
South Florida Institutional Review Board. Patients were ap-
proached in the waiting room by a researcher from the Health
Outcomes and Behavior program and asked whether they
would participate in a survey about their expectations of the
hospital. Patients were told the interview would take approx-
imately 20 minutes and they could choose to cease partici-
pation at any time during the interview. Patients who agreed
signed consent forms and were then told they would receive
a $10 gift certificate to a local bakery. The consent form told
patients that the final results would be disseminated in aggre-
gate form, meaning summaries with names and identifying
information would be removed. Five patients refused, citing
they did not feel well enough. Two patients asked whether the
interview could be completed over the telephone at a later
time. In total, 43 interviews were conducted. Participants
ranged in age from 42 to 74, and 25 were male and eight were
female. Thirty-seven of the respondents were white, four
were African American, one was Asian, and one was His-
panic. The racial and ethnic composition of the participants is
comparable with the overall patient population of the hospital
where the research was conducted. Patients enrolled in clin-
ical trials at this cancer center between 2001 and 2006 were
primarily white (96.33%), non-Hispanic (92.84%) males
(55.69%). Patients’ ages ranged from 17 to 93, with an
average age of 64.33 (SD  10.99).
Procedure
Questions for the in-depth interviews were developed
based on common factors in the literature and focused on
participants’ (1) knowledge of clinical trials, (2) attitudes
toward clinical trials, (3) behavioral intentions regarding
participation in a clinical trial, (4) reasons for coming to this
cancer center, and (5) use of the Internet for information
about lung cancer treatment (Table 2 contains a summary of
TABLE 1. Comparison of Percentage of Patients Accrued to Specific Cancer Trials With Percentage of Cancer Cases
Nationwide by Sex for Four Types of Cancer
Cancer
Subtype
Males Females
No. of
Annual Cases
No. of
Trial Patients
% US Cancer
Burden
% Cancer
Trial Patients
No. of
Annual Cases
No. of
Trial Patients
% US Cancer
Burden
% Cancer
Trial Patients
Colorectal 67,300 1,130 10.5 11.2 68,100 916 10.9 7.0
Lung 90,700 928 14.1 9.2 78,800 608 12.6 4.6
Lymphoma 35,500 468 5.4 4.6 28,600 266 4.6 2.0
Leukemia 17,700 2,265 2.8 22.5 13,800 1,771 2.2 13.6
Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer program affect accrual to cancer treatment trials. J Clin
Oncol 2002;2:2109–2117; reprinted with permission from the American Society of Clinical Oncology.
TABLE 2. In-Depth Interview Questions
1. Where do you get information about your health?
2. How did you make the decision to come to Moffitt Cancer Center?
3. Do you know what a clinical trial is?
a. Have you ever participated in a clinical trial?
4. Can you give an example of one?
a. What type of trial did you participate in?
5. Have you ever discussed clinical trials with a health care professional?
a. How was the trial discussed with you?
6. Do you anticipate being offered a clinical trial?
a. Are you satisfied with your decision to participate in a trial?
7. If offered a trial, how do you think you would respond?
a. Do you have any regrets about being in the trial?
8. Who would be involved or who would help you make a decision
about whether you participated in a clinical trial?
a. Did you make the decision alone? Who participated in the
decision making process?
9. Have you ever used the Internet to search for information about your
health?
10. Is there anything you wish you had known before you began the trial?
Anything you think other people would benefit from knowing?
11. Any other comments?
Questions in italics indicate modifications made for former clinical trial participants.
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the interview questions). Additionally, established patients
who had participated in a treatment trial were asked to
comment on their satisfaction with the clinical trial process
and outcomes. During the interviews, issues that were more
relevant to a particular participant were probed in greater
depth. All interviews were audiotaped and transcribed.
Data Analysis
Texts of participants’ interview responses were initially
hand coded and later managed with The Ethnograph com-
puter software program version 5.07.10 Each interview was
transcribed within 24 hours. To help determine when satura-
tion occurred, data were collected and analyzed concurrently.
Content analysis, using a template analysis plan, was per-
formed to identify major themes in lung cancer patients’
beliefs and experiences with clinical trials.11 Two researchers
used an initial code list (developed before data analysis based
on themes included in interview questions, e.g., a line of text
was coded as “attitude toward clinical trials”) and the open-
coding process throughout the analysis process (e.g., new
codes or themes emerged such as “fear of being offered a
clinical trial”). Each researcher independently reviewed the
data twice.
In the first coding attempt, researchers read the entire
text of a transcript, applying the initial codes to the data while
also making notes on possible new codes. After each re-
searcher completed the first round of coding, they discussed
their notes on probable new codes. After consensus was
reached, a new codebook was created and coders once again
independently reviewed the data and updated code categories
from the first coding pass. After the second coding pass, the
researchers met to discuss coding similarities and discrepan-
cies. To check for coding validity and reliability, interrater
reliability was established by counting the number of content
areas to be coded, divided by the number of agreements.12
Final data analysis was conducted with an interrater reliabil-
ity rate of 0.80 (Cronbach ). Summaries of the coded data
were provided to the research team and discussed with the
intent of developing an intervention to address issues from
the patient perspective.
Intervention Development
Data from the in-depth interviews revealed both new
and existing patients had misperceptions of clinical trials and
misplaced trust in the standard treatment for lung cancer. To
alleviate some of these misperceptions, the research team
developed a letter and accompanying protocol for all new
thoracic patients. The letter, produced in both English and
Spanish, advised patients that the cancer center was a re-
search hospital, and, as such, discussions and presentation of
clinical trials were the “norm” for all patients. Patients were
told to expect these discussions and to anticipate that every
physician was hopeful each patient would participate in some
type of clinical trial while a patient at the cancer center. The
letter also explained that trials were an option, as was stan-
dard treatment, and physicians would work with the patient
and family members to find the option that offered the best
possible prognosis for the patient and his or her disease. See
Table 3 for a copy of the letter.
RESULTS
Formative Research Phase
Results from the interviews revealed that new patients
and existing patients had similar perceptions of clinical trials
including fear of being a guinea pig, the offering a trial meant
no hope, and misconception of purpose. For example, approxi-
mately half of the patients interviewed said they feared clinical
trials for the following reasons:
Y Being a guinea pig—being used to further the career of
a scientist without benefit to one’s present condition,
Y Assuming all clinical trials involve a placebo and pa-
tients “runs the risk” of receiving the placebo (i.e.,
getting no treatment) and dying sooner,
Y Personal belief they have little time left and their time
would be shortened by participating in a clinical trial.
When new patients and established oatients were asked
whether would participate in a clinical trial if their physician
offered it, most patients expressed concern. The majority said
they did not really know what a clinical trial was or felt that
trials were
Y a last chance for someone who has no hope,
Y what one does when the current treatment is not working
Y an indication by the physician that death from cancer is
imminent,
Y for rare types of cancer or unknown disease.
Yet, despite these expressions of misgivings and con-
cerns the majority of respondents said they would participate
in a trial if offered one by the physician.
TABLE 3. Example Letter Sent to New Thoracic Patients*
Dear [insert name],
Thank you for your interest in coming to the Thoracic Oncology Clinic at
the H. Lee Moffitt Cancer Center & Research Institute. I understand
that you will be having your first appointment with me, so I want to let
you know what to expect. This important letter is being sent by all of
our program physicians to their new patients.
I am one member of a group of physician specialists who have the
expertise to diagnose and treat lung cancer. Our Cancer Center has the
very best treatment options available; however, the best is still not good
enough. That is why we are actively working on research and special
treatments called clinical trials for many of our patients. We believe
this is the most effective way for many patients to receive the best care
possible, and for all of us to contribute to the prevention and cure of
lung cancer in the future.
When we meet, I would like to hear what is on your mind. I will answer
your questions and talk about your concerns. I will also ask you some
questions. This will help me to get to know you and your current health
condition. Then, I will tell you about clinical trials and other types of
treatments available and what I believe is the best option for you.
Together, we will develop a treatment plan that will enable you to work
toward your own goals. I am looking forward to meeting you and
helping you to make some important decisions about your health care.
Sincerely,
Charles C. Williams, Jr., M.D.
*An equivalent Spanish version of the letter was also developed and sent to patients
whose primary language was Spanish.
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The majority of the new and existing patients came to
this hospital looking for “hope” or advanced treatment op-
tions. Similarly, most of the patients came to this cancer
center for a second opinion and ultimately transferred here as
their primary source of care. Most patients did not report
using the Internet to seek out additional information about
their disease, treatment, or diagnosis. However, many said
their family members, particularly adult children, often did
use a computer or library to search for expanded definitions
of their diagnosis, look for treatments and find psychosocial
or support group services.
The majority of established patients who had previ-
ously participated in a treatment trial were unable to distin-
guish between making a decision to come to the cancer center
to seek treatment and agreeing to a clinical trial. When asked,
“How did you make the decision to participate in a clinical
trial?” the majority of patients talked about their decision to
come to the cancer center or the events that led them to switch
health care systems/providers. When probed for family or
other influence in the decision-making process, all but one
patient said “My doctor suggested the trial and I trust him.”
Many former treatment trial participants were attracted to
particular words or phrases used by their physician and used
these to accentuate the reason why they were pleased with
their decision to come to the cancer center and/or participate
in a trial.
Dr. ____ said we were going to treat this thing aggressively and
that’s just what I wanted to hear.
Dr. ____ said “we” whenever he talked about the cancer. It
made me feel like I wasn’t alone. We were in this together.
The former trial participants were asked if they felt
confident or regretted the decision to participate in a clinical
trial, and all responded favorably, even those whose health
did not improve as a result of the trial. In the majority of
cases, the former trial participants did not distinguish be-
tween the trial and the cancer center itself. People responded
with such comments as “When you trust the doctor and
hospital, you trust the procedure.”
Patients who had participated in a trial were asked to
respond to the fears often expressed by new patients, such as
fear of being a guinea pig in a clinical trial or fear that the
offering of a trial meant the patient had little time left. All
former trial participants articulated this was not the way they
felt. The majority said their physicians thoroughly explained
the trial to them and what it meant for their specific condition
in relation to standard treatment. In fact, many saw the trial as
a sign of hope, particularly if they had seen another physician
elsewhere and were offered few options.
It wasn’t an issue for me. I joked to my friends that I was going
to be a guinea pig— and it really was a joke. I felt very familiar
with the process. And what I was going to get out of it was far
more than any other doctor had suggested.
Only one former trial participant recalled having a
conversation about clinical trials in general and knew the
type/phase of trial she was participating in (this patient was
also a health care provider.) The majority of participants said
they did not know that trials were categorized in phases. Also,
one patient wondered whether she had been offered the trial
because other options were not working.
I always wondered if this was a “Hail Mary.” It wouldn’t have
changed my decision to go on the trial, but would have been nice
to know.
When asked to describe the most positive aspect of
participating in a trial, most former trial participants de-
scribed the care they received during treatment.
I felt privileged to be on a trial. We had a separate chemo facility
and we all knew we were at the Ritz.
I don’t think I got special treatment because I was on a trial, I
think _____ treats all patients special, that’s part of why we
came here. But we sure did get good treatment.
Although no former trial participants said they regretted
their decision to participate in the trial, approximately half
said they had some unanswered questions. Some said they
found themselves unable to explain to family or friends why
they were participating in the trial other than to say their
physician had recommended it and they trusted their physi-
cian. Others said they were not sure why certain procedures
were performed during the trial, such as being weighed, the
timing of receiving treatment, and why their dose/procedure
was different from that of other patients. However, none of
these patients said their concerns ever caused them to doubt
or regret their decision. Some said they felt that when they
made the decision to be in a trial it came with the decision to
trust the doctors implicitly. Others said they thought if these
details were necessary for them to know, it would have been
explained to them. Still others felt asking too many questions
would imply a sense of doubt, and they never wanted their
care providers to feel they were being suspicious.
I’m the type of patient you can give too much information
to—you can put me off the process if it requires me to listen too
much or make too many decisions.
I didn’t think it was my job to understand it all and too many
questions might make these guys rethink what they are doing. If
it’s going well, why ask questions?
A few former trial participants said they wished they
knew more about the results of the trial in which they had
participated. These patients said they would like to know
what the research was finding or whether other patients were
getting the same results as they did.
It would be good to know where they went with this stuff. What
did they find? Did they keep going?
Years from now, even if I’m gone, I’d love for my family to get
a newsletter from _____ telling me the results of the trial. I’d like
to know that I helped contribute to the motto. I would think it would
be a good fundraising technique as well. We were part of the
battle—we’d like a war progress report.
All former trial participants said they had complete
support from family members to participate in the trial and
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both family members and patients were kept well informed
by the staff. Most said they had given permission for a family
member to speak directly to staff if necessary and that their
family’s questions were answered and phone calls were
returned.
All former trial participants said they felt more knowl-
edgeable about trials and research since participating in a
clinical trial. Approximately half said they openly discussed
the trial in social settings. The other half felt their medical
information was private and not appropriate to talk about with
others outside the family.
I don’t like talking about my cancer with other people. I don’t
like answering their questions or sharing that information about
myself.
When asked what they thought other patients should
know about trials or what they wished they had known before
participating in the trial, former trial participants had a variety
of responses:
I don’t know what other people need to know? It would be good
for people to be told up front how bad the chemo is. How
incredibly tired you feel. That can’t be said enough.
If patients are confident in their doctor, who is going to say no?
The trick is to get people in here at the right time.
Intervention Development
Between August of 2003, when the new patient letter
was introduced and sent to new thoracic patients before
their first appointment and August of 2004, lung cancer
patient enrollment at this cancer center increased 18% and
approximately 81% of all eligible lung cancer patients
were in a trial (Table 4). The 81% is based on all new
patients seen in the thoracic program. Every patient is
discussed in the multidisciplinary conference, and all pa-
tients eligible for a therapeutic trial are marked as “trial
eligible,” which makes up the denominator. This denomi-
nator is of course limited to those patients eligible for a
trial. Patients who are actually enrolled in a trial by signing
an informed consent document are the numerator. The
letter continues to be used today, and the numbers of new
eligible patients enrolling on clinical trials has remained at
a high level.
DISCUSSION
In the United States, the incidence of newly diagnosed
lung cancer in 2006 is expected to be 174,470 with approx-
imately 162,460 deaths occurring.13 Lung cancer contributes
to 30% of male and 27% of female cancer-related deaths and
is the leading cause of cancer-related mortality in both men
and women.14 For most lung cancer patients, combination
chemotherapy is essentially palliative and produces low mea-
surable responses (15%–35%) with complete responses being
rare and eventual disease progression inevitable.15 However,
at present, there are clinical trials under way in which initial
results show greater promise for patients with stage IV
disease.16 The current 5-year survival rate is 15% and has not
increased significantly in the past 10 years.17 Clinical trials
are thought to be the best means for finding new cancer
treatments and cures, yet significant numbers of cancer pa-
tients, especially lung cancer patients, do not participate in a
trial. Poor accrual rates prevent the ability to answer impor-
tant research questions in a timely manner. Additionally,
without diverse participation by age and gender, the ability
for results to be considered generalizable to all thoracic
patients is greatly affected.
The data from this study suggest that lung cancer
patients have a great many misperceptions about clinical
trials. They do not understand their purpose and fear being
offered a trial. It is not known whether these misperceptions
stem from the fact that the average lung cancer patient tends
to be older, older than age 65,15 or are related to the increased
psychological distress suffered by lung cancer patients, or
from other factors. However, what does appear consistent
across lung cancer patients is that trust in the institution and
the physician is the key to clinical trial participation. The
strength of the patient-physician relationship in clinical trial
accrual has been cited in many other studies.18–22 Providing
new lung cancer patients information about clinical trials via
a letter mailed to them before their first appointment shows
promising signs of alleviating patients’ fear of being offered
a clinical trial and thereby increasing trial participation.
Based on the first year of data, it seems that our efforts to
address patients’ fears and concerns regarding clinical trials
and to correct misconceptions before their first appointment
in the Thoracic Program, has been successful in increasing
lung cancer patient enrollment in clinical trials. However, it is
important to note that the current research should be viewed
as a case study. There was no control group in the study, nor
can it be determined that the letter directly caused the in-
crease in accrual rates. Nonetheless, this project represents an
innovative procedure for demystifying clinical trails for lung
cancer patients. Future research should build on these pre-
liminary findings and replicate the letter process in a larger
study to increase the generalizability of our findings.
Further, although the letter appears to have been suc-
cessful in increasing accrual rates among patients eligible for
a clinical trial, roughly 64% of lung cancer patients who
come to the center are ineligible for any trial. The primary
reason for their ineligibility is having begun treatment else-
where. More concentrated research is needed to understand
how to promote clinical trials to patients before they begin
TABLE 4. Clinical Trial Trends in the Thoracic Oncology
Program
Date
Total No. of
New Patients
Total No. of Open
Phase II or III
Treatment Trials
% Patients
on Trial
August 2001 85 3 8
August 2002 144 11 10
August 2003 105 13 17
August 2004 73 9 33
The number of 33% is derived by using all new patients to thoracic as the
denominator, regardless of whether they are eligible for any actively enrolling trials.
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standard treatment. Newly diagnosed patients and the general
public need more education regarding the relative lack of
efficacy of standard treatment for lung cancer. Cancer re-
searchers should also strive toward developing treatment
trials for patients who may have already received previous
therapy. These efforts, combined with positive media cover-
age about patients in trials and more concentrated outreach
efforts to dispel myths about randomization and trial types,
may go a long way in battling misperceptions of research and
the war on cancer.
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